# enGene Therapeutics (ENGN) — News

ENGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/engn/news

## Recent headlines

- [CMA CGM - From 2029, this facility, developed by Engie, will supply 7,000 tonnes of biomethane (equivalent to 100 GWh) each year to the CMA CGM fleet](https://www.ainvest.com/news/cma-cgm-2029-facility-developed-engie-supply-7-000-tonnes-biomethane-equivalent-100-gwh-year-cma-cgm-fleet-2610) — AInvest Wire, Oct 13, 2026
  CMA CGM has announced a new initiative in its ongoing efforts to achieve carbon neutrality by 2050, with a facility developed by Engie set to supply 7,000 tonnes of biomethane annually, equivalent to 100 gigawatt-hours (GWh), to the CMA CGM fleet starting in 2029. This development aligns with the…
- [Perceptive Advisors reduces ASND, ENGN, Naut, ABVX in 2Q: 13F](https://www.ainvest.com/news/perceptive-advisors-reduces-asnd-engn-naut-abvx-2q-13f-2608) — AInvest Wire, Aug 14, 2026
  Perceptive Advisors LLC, a hedge fund managed by Joseph Edelman, has disclosed its 13F filings for the first quarter of 2026, revealing several notable changes in its portfolio. Among the most significant adjustments are reductions in holdings of Ascendis Pharma A/S (ASND), enGene Holdings Inc.…
- [Engene Therapeutics - appoints Michael Heffernan as chairman of the board - SEC filing](https://www.ainvest.com/news/engene-therapeutics-appoints-michael-heffernan-chairman-board-sec-filing-2607) — AInvest Wire, Jul 16, 2026
  Engene Therapeutics Inc. has announced the appointment of Michael Heffernan as chairman of its board of directors, according to a recent SEC filing [1]. Heffernan brings extensive experience in the biotechnology and pharmaceutical sectors, having previously held leadership roles at several publicly…
- [Engene: Michael Heffernan assumes chairman role](https://www.ainvest.com/news/engene-michael-heffernan-assumes-chairman-role-2607) — AInvest Wire, Jul 16, 2026
- enGene fall 12% to $19.17 after peaking at $43 following SPAC deal — AInvest Wire, Nov 1, 2023

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).